Globus Medical (NYSE:GMED) Announces Earnings Results

Key Points

• Globus Medical reported quarterly EPS of $1.23, beating the $1.20 consensus, but revenue of $763.7 million missed estimates and fell 0.7% year over year.
• The company cut its 2026 revenue outlook to about $3.09 billion, citing weak Nevro sales and delayed or limited product contributions, while reiterating EPS guidance of $4.95–$5.05.
• Despite the revenue shortfall, adjusted gross margin improved and free cash flow hit a record $225 million; the board also authorized an additional $500 million share-repurchase program.

Globus Medical (NYSE:GMED - Get Free Report) announced its quarterly earnings results on Thursday. The medical device company reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $1.20 by $0.03, FiscalAI reports. Globus Medical had a return on equity of 14.51% and a net margin of 17.76%. The business had revenue of $763.72 million for the quarter, compared to analysts' expectations of $792.39 million. During the same period in the previous year, the firm earned $1.18 EPS. The business's quarterly revenue was down .7% on a year-over-year basis. Globus Medical updated its FY 2026 guidance to 4.950-5.050 EPS.

Here are the key takeaways from Globus Medical's conference call:

• Q3 revenue declined 0.7% to $763.7 million, as 3% growth in the base business excluding Nevro was offset by Nevro’s 25.7% decline. U.S. Spine grew 2%, held back by delayed product launches and lower-than-expected contributions from competitive recruiting.
• Globus lowered its 2026 revenue outlook to $3.09 billion from $3.18 billion–$3.22 billion, citing Nevro weakness and limited contribution from new products this year. It reiterated non-GAAP EPS guidance of $4.95–$5.05.
• Profitability and cash generation improved despite the revenue decline: non-GAAP EPS rose 4% to $1.23, adjusted gross margin expanded 140 basis points to 69.5%, and free cash flow reached a record $225 million.
• Management expects new spine products—including SCRIPT, XLIF Prone, and eIQ—and greater robot and navigation pull-through to support growth in 2027 and beyond. Enabling Technologies revenue grew 24% in Q3, while deployed units rose 45% year over year.
• The board authorized an additional $500 million share-repurchase program; Globus repurchased $142.9 million of shares in Q3. Management also expects continued margin improvement, while noting that higher R&D investment is planned.

Globus Medical Stock Performance

GMED stock traded down $10.77 on Friday, reaching $70.67. The company's stock had a trading volume of 9,272,194 shares, compared to its average volume of 1,418,585. The firm has a market cap of $9.49 billion, a PE ratio of 14.30, a PEG ratio of 1.14 and a beta of 0.98. The business has a fifty day simple moving average of $77.20 and a two-hundred day simple moving average of $83.18. Globus Medical has a 12-month low of $70.39 and a 12-month high of $101.40.

Insider Buying and Selling at Globus Medical

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares of the company's stock, valued at approximately $2,176,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ann Rhoads sold 5,000 shares of the company's stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares of the company's stock, valued at $3,007,640. This trade represents a 12.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 60,000 shares of company stock valued at $4,838,400. 18.38% of the stock is currently owned by company insiders.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Needham & Company LLC cut their target price on shares of Globus Medical from $117.00 to $100.00 and set a "buy" rating on the stock in a report on Friday. Canaccord Genuity Group lowered their price target on shares of Globus Medical from $115.00 to $105.00 and set a "buy" rating for the company in a report on Friday. Royal Bank Of Canada dropped their price target on shares of Globus Medical from $115.00 to $85.00 and set an "outperform" rating for the company in a research report on Thursday, October 1st. UBS Group initiated coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a "neutral" rating and a $82.00 price target for the company. Finally, BTIG Research reissued a "neutral" rating on shares of Globus Medical in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $96.92.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.